查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994189

癌症谱分析市场：2026-2032年全球市场预测（按癌症类型、技术、检体类型、生物标记类型、应用和最终用户划分）

Cancer Profiling Market by Cancer Type, Technology, Sample Type, Biomarker Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，癌症分析市场价值将达到 131.1 亿美元，到 2026 年将成长至 145.1 亿美元，到 2032 年将达到 288.1 亿美元，复合年增长率为 11.89%。

主要市场统计数据
基准年 2025 131.1亿美元
预计年份：2026年 145.1亿美元
预测年份：2032年 288.1亿美元
复合年增长率 (%) 11.89%

本文简要概述了癌症分析领域的最新技术、临床和营运趋势，为诊断和治疗领域的相关人员提供策略决策指南。

本执行摘要整合了癌症分析技术、临床应用和终端用户采纳趋势的最新进展，旨在为诊断、治疗和研究领域的相关人员提供策略规划支援。摘要重点在于技术创新与临床需求的交汇点，揭示了不断发展的检测能力、检体工作流程和生物标记策略如何重塑诊断决策和转化研究路径。

定序、非侵入性取样和综合生物标记策略的快速创新如何重新定义癌症分析的临床工作流程和商业性伙伴关係？

定序精度、多重检测和检体独立分析模型的显着进步正在变革癌症谱分析，拓展临床医生可采取的实用决策范围。长读长和短读长定序技术整合到诊断流程中，能够捕捉以往难以检测的复杂基因组重排和结构突变，从而实现对肿瘤生物学特征和抗药性机制更精细的分层分析。

本文展望了 2025 年的关税措施将如何重塑癌症诊断和研究领域中相关人员的供应链、定价趋势和策略采购选择。

将于2025年实施的新关税措施将对癌症基因分型相关人员产生多方面的影响，包括供应链、筹资策略和跨境合作。对于定序仪和检测试剂盒的製造商而言，某些组件和成品进口关税的提高可能会推高整体成本，迫使供应商重新评估其定价、采购和库存管理策略。这一趋势将促使诊断实验室和医院重新评估其试剂采购週期，并协商在不影响临床能力的前提下，维持高价值检测资源供应的合约。

细分市场分析揭示了癌症类型、技术选择、检体基质、生物标记分类、应用和最终用户需求如何共同决定临床和商业性优先事项。

透过细分获得的洞见揭示了临床效用、技术成熟度和最终用户需求之间的交集，从而在癌症谱分析的整体情况中创造了机会和风险。基于癌症类型，骨髓恶性肿瘤和固态肿瘤之间的差异导致了不同的检测重点。血液系统恶性肿瘤的工作流程着重于检测白血病、淋巴瘤和多发性骨髓瘤的特定融合事件、克隆动态和微量残存疾病，而固态肿瘤谱分析则着重于乳癌、结直肠癌、肺癌和前列腺癌中治疗关键突变和肿瘤异质性。这些不同的临床目标决定了检查室操作中的检测方法选择、检体处理和报告细节。

区域观点下的部署管道、监管差异以及影响癌症分析解决方案公平取得和推广的基础设施要求。

区域趋势对全球癌症基因谱分析的可及性、应用率和策略重点起着至关重要的作用。在美洲，对精准肿瘤学基础设施的投资、下一代测序技术的广泛应用以及整合医疗网络的建设，都为新型检测方法的快速临床应用提供了支持；与此同时，市场参与企业必须应对复杂的报销机制和检查室认证的差异。该地区通常在医疗设备製造商和製药公司之间的伴随诊断合作中发挥主导作用，从而形成丰富的研发管线，用于进行实施研究和产生真实世界数据（REW）。

伴随诊断领域的策略专业化、整合服务模式和合作伙伴关係如何定义竞争优势并实现可扩展的临床部署？

主要企业和研究机构正透过结合专业化、垂直整合服务、检测方法开发和资讯学以及临床支援的合作模式来脱颖而出。一些公司专注于平台卓越性，提供检验的仪器、耗材和标准化的工作流程，从而实现高性能诊断；而其他公司则专注于特定临床应用，例如微量残存疾病检测和复杂结构突变的解析。技术提供者与製药开发公司之间的策略伙伴关係日益普遍，将伴随诊断的开发与治疗产品线相结合，以简化监管核准和市场准入流程。

为领导者制定可操作的策略重点，以加速分析解决方案的部署和管理，建立供应链弹性、临床检验路径和互通服务。

产业领导者应优先投资于能够增强韧性、临床有效性和与医疗服务路径无缝整合的领域。提高供应链透明度和采购柔软性可以降低关税和物流风险，而对本地製造和分销的定向投资可以缩短前置作业时间，并确保关键耗材的稳定供应。同时，各机构应投资跨平台检验研究，以证明不同技术的兼容性，并支援电子医疗系统间临床报告的互通性。

透过与专家对话、整合技术文献以及与检查室标准交叉检验，高度透明且以实践者为中心的调查方法确保了实用见解。

本执行摘要的调查方法结合了第一手和二级资讯来源、专家访谈以及结构化的综合分析，旨在对技术、临床和商业性趋势进行平衡评估。第一手资料包括与实验室管理人员、临床研究人员和行业高管的对话，以了解实际营运情况、证据要求和推广应用障碍。除这些定性研究外，还仔细查阅了同行评审文献、监管指南和技术白皮书，以支持技术说明和临床应用定义。

最终的综合分析将重点放在技术、证据和营运韧性之间的关键交互作用，从而确定哪些分析技术能够产生持久的临床影响。

总之，癌症基因分型正处于一个转折点，技术进步、法规演进和供应链变化相互交织，既带来了机会，也带来了营运挑战。最成功的机构很可能将可靠的检测技术与检验的工作流程、快速的供应策略以及以临床医生为中心的报告相结合，从而直接支持治疗决策。为了将分析能力转化为常规临床应用，跨平台检验和证据产生至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 癌症谱分析市场：依癌症类型划分

  • 骨髓恶性肿瘤
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
  • 固体癌
    • 乳癌
    • 结肠癌
    • 肺癌
    • 摄护腺癌

第九章：癌症基因分型市场：依技术划分

  • 萤光原位杂合反应
  • 免疫组织化学
  • 微阵列
  • 下一代定序
    • 长读长定序
    • 短读定序
  • 聚合酵素链锁反应

第十章 癌症基因谱分析市场：依检体类型划分

  • 血
    • 电浆
    • 血清
    • 全血
  • 唾液
  • 尿

第十一章 癌症谱分析市场：依生物标记类型划分

  • 基于DNA的
  • 基于蛋白质
  • 基于RNA的

第十二章 癌症基因分型市场：依应用领域划分

  • 诊断
  • 监测
    • 液态生物检体
    • 微量残存疾病
  • 预后
  • 研究
  • 治疗方法方案
    • 伴随诊断
    • 药物基因体学

第十三章 癌症基因分型市场：依最终用户划分

  • 诊断检测实验室
  • 医院
  • 製药公司
  • 研究机构

第十四章 癌症基因分型市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 癌症基因分型市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 癌症基因分型市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国癌症基因分型市场

第十八章：中国癌症基因检测市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 4basecare Onco Solutions Private Limited
  • ACT Genomics Co., Ltd. by Prenetics Global Limited
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • BostonGene Corporation
  • Caris Life Sciences
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • GENINUS Inc.
  • Genomic Life
  • GenScript BIoTech Corporation
  • Guardant Health, Inc.
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • IMBdx, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health, Inc.
  • Merck KGaA
  • NanoString Technologies, Inc.
  • Neogenomics, Inc.
  • Nonacus Limited
  • OncoDNA SA
  • Oncompass Medicine Hungary Kft.
  • Paragon Genomics, Inc.
  • Personalis, Inc.
  • Perthera, Inc.
  • Qiagen NV
  • Renovaro Biosciences Inc.
  • Strand Life Sciences
  • Sysmex Corporation
  • Takara Bio Inc.
  • Tempus Labs Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C046A

The Cancer Profiling Market was valued at USD 13.11 billion in 2025 and is projected to grow to USD 14.51 billion in 2026, with a CAGR of 11.89%, reaching USD 28.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.11 billion
Estimated Year [2026] USD 14.51 billion
Forecast Year [2032] USD 28.81 billion
CAGR (%) 11.89%

A concise synthesis of recent technological, clinical, and operational dynamics in cancer profiling that frames strategic decisions for diagnostics and therapeutic stakeholders

This executive summary synthesizes contemporary developments in cancer profiling technologies, clinical applications, and end-user adoption trends to inform strategic planning for stakeholders across diagnostics, therapeutics, and research. It focuses on the intersection of technological innovation and clinical need, highlighting how evolving assay capabilities, sample workflows, and biomarker strategies are reshaping diagnostic decision-making and translational research pathways.

The narrative emphasizes practical implications for clinical laboratories, hospitals, pharmaceutical developers, and research institutions by integrating recent advances in next-generation sequencing, molecular assays, and liquid biopsy approaches with shifting supply chain dynamics and regulatory expectations. It situates these developments within broader healthcare imperatives such as precision oncology, molecularly informed therapy selection, and real-world evidence generation. The intent is to provide readers with a concise, actionable foundation for aligning investment, operational, and clinical strategies with the most impactful trends in cancer profiling today.

Through a combination of technology-focused analysis and end-user perspectives, the summary also identifies critical dependencies-such as reagent availability, sample handling standards, and data interpretation infrastructures-that will determine which innovations achieve routine clinical utility. The content is designed to be relevant for executives, clinical leaders, and laboratory directors seeking to weigh technology choices and partnership opportunities against evolving clinical demands and regulatory pathways.

How rapid innovations in sequencing, noninvasive sampling, and integrated biomarker strategies are redefining clinical workflows and commercial partnerships in cancer profiling

Cancer profiling is undergoing transformative shifts driven by leaps in sequencing fidelity, assay multiplexing, and sample-agnostic analytic models that expand the actionable window for clinicians. Advances in long-read and short-read sequencing modalities are being integrated into diagnostic pipelines to capture complex genomic rearrangements and structural variants that were previously elusive, enabling finer stratification of tumor biology and resistance mechanisms.

Concurrently, improvements in noninvasive sampling and liquid biopsy sensitivity are extending the utility of monitoring and minimal residual disease detection, while immunohistochemistry and fluorescence in situ hybridization continue to provide rapid, tissue-based context for therapeutic decisions. These technological refinements are supported by enhanced bioinformatics toolchains that reduce interpretive variability and accelerate turnaround times, fostering broader adoption among diagnostic laboratories and hospitals.

Parallel to laboratory innovations, the landscape is shifting toward modular workflows that prioritize interoperability, standardized reporting, and cross-platform validation. This movement is reinforced by stakeholders' demand for companion diagnostics and pharmacogenomic insights that directly inform therapy selection, driving closer collaboration between assay developers and pharmaceutical companies. As a result, the paradigm is moving from isolated tests toward integrated diagnostic ecosystems that combine DNA-based, RNA-based, and protein-based biomarkers to deliver multidimensional clinical intelligence.

Finally, the cumulative effect of these shifts is altering value propositions across the care continuum: early and accurate molecular characterization reduces diagnostic odysseys, enables targeted enrollment into clinical trials, and supports adaptive treatment strategies. The implication for market participants is clear: success will depend on delivering reproducible, clinically actionable results at scale, supported by robust logistics, compliant data governance, and sustainable commercial models that align incentives across providers, payers, and developers.

Anticipating how 2025 tariff measures reshape supply chains, pricing dynamics, and strategic sourcing choices for cancer profiling stakeholders across diagnostics and research

The introduction of new tariff measures in the United States in 2025 presents a multifaceted set of implications for cancer profiling stakeholders, affecting supply chains, procurement strategies, and cross-border collaboration. For manufacturers of sequencing instruments and assay kits, increased import duties on select components and finished goods can elevate landed costs, prompting suppliers to reassess pricing, sourcing, and inventory practices. This dynamic will exert pressure on diagnostic laboratories and hospitals to reevaluate reagent purchasing cycles and to negotiate contracts that preserve access to high-value assays without compromising clinical throughput.

Beyond direct cost effects, tariffs can catalyze strategic responses such as supplier diversification, nearshoring of critical manufacturing steps, and greater emphasis on regional distribution hubs to mitigate lead-time volatility. These adaptations may improve resilience in the medium term but require upfront capital and operational changes that can temporarily disrupt service delivery. In parallel, research institutes and pharmaceutical companies that depend on imported specialized reagents and instrumentation may face project delays or increased study costs, influencing timelines for biomarker validation and companion diagnostic development.

Tariff-driven price adjustments also have downstream implications for adoption of advanced technologies such as long-read sequencing or high-content platforms. Providers in resource-constrained settings may prioritize established, lower-cost methodologies like immunohistochemistry and polymerase chain reaction, slowing diffusion of higher-cost but clinically informative technologies. Conversely, payers and health systems may accelerate consolidation of testing within centers of excellence to preserve access to comprehensive profiling while containing overall expenditure.

On the regulatory and policy front, tariffs can prompt dialogue between industry and government about strategic importance of biotech supply chains, potentially accelerating incentives for domestic manufacturing, public-private partnerships, and targeted investments in local capacity. These policy responses may reduce long-term vulnerability but will also shape competitive dynamics and the distribution of manufacturing expertise globally. Collectively, the tariff environment underscores the importance of supply chain transparency, flexible sourcing strategies, and proactive stakeholder engagement to ensure continuity of high-quality cancer profiling services.

Segment-level analysis revealing how cancer type, technology choice, sample matrix, biomarker class, application purpose, and end-user requirements jointly determine clinical and commercial priorities

Insights derived from segmentation illuminate where clinical utility, technology maturity, and end-user needs converge to create opportunity and risk across the cancer profiling landscape. Based on cancer type, differences between hematologic malignancies and solid tumors drive distinct testing priorities: hematologic workflows emphasize detection of specific fusion events, clonal dynamics, and minimal residual disease across leukemia, lymphoma, and multiple myeloma, while solid tumor profiling concentrates on actionable mutations and tumor heterogeneity within breast, colorectal, lung, and prostate cancers. These divergent clinical goals inform assay selection, sample handling, and reporting granularity in laboratory operations.

Based on technology, the diagnostic toolkit spans fluorescence in situ hybridization, immunohistochemistry, microarray platforms, next-generation sequencing, and polymerase chain reaction. Within next-generation sequencing, the emergence of both long-read sequencing and short-read sequencing enables complementary interrogation of genomic complexity: short-read approaches provide high-throughput mutation detection and cost-efficiency, while long-read methods resolve structural variants and repetitive regions that have clinical relevance for specific tumor types. The choice of technology is shaped by clinical indication, turnaround time requirements, and the analytic sensitivity necessary for monitoring and early detection.

Based on sample type, blood, saliva, and urine each offer unique advantages and constraints. Blood-derived analyses-including plasma, serum, and whole blood-support both tumor genotyping and longitudinal monitoring via circulating tumor DNA, whereas saliva and urine present noninvasive alternatives for certain tumor types and patient populations. Sample matrices influence pre-analytical workflows, cold chain logistics, and interpretation frameworks, requiring laboratories to standardize collection protocols to preserve assay performance.

Based on biomarker type, DNA-based, protein-based, and RNA-based markers provide orthogonal insights that enhance diagnostic confidence and therapeutic alignment. DNA analyses excel at identifying somatic and germline variants; RNA-based assays reveal gene expression patterns and fusion transcripts; and protein-based measurements capture phenotypic states that can predict drug response. Integrating these biomarker classes into composite reports increases clinical actionability but demands harmonized validation and cross-platform comparability.

Based on application, diagnosis, monitoring, prognosis, research, and therapy selection define the primary use cases for profiling technologies. Monitoring use cases such as liquid biopsy and minimal residual disease require assays with exceptional sensitivity and reproducibility, while therapy selection relies on companion diagnostics and pharmacogenomics to match patients to targeted therapies and dosing strategies. Each application imposes different demands on assay design, regulatory documentation, and evidence generation.

Based on end user, diagnostic laboratories, hospitals, pharmaceutical companies, and research institutes exhibit distinct operational constraints and value drivers. Diagnostic laboratories prioritize throughput, reproducibility, and reimbursement pathways; hospitals focus on integration with clinical workflows and electronic health records; pharmaceutical companies seek robust biomarker validation and companion diagnostic alignment for drug development; and research institutes emphasize exploratory analyses and novel target discovery. Recognizing these user-specific imperatives is essential for tailoring product design, service models, and commercialization strategies.

A regional perspective on adoption pathways, regulatory variability, and infrastructure requirements that influence equitable access and scale-up of cancer profiling solutions

Regional dynamics play a decisive role in shaping access, adoption rates, and strategic priorities for cancer profiling across the globe. In the Americas, investments in precision oncology infrastructure, widespread adoption of next-generation sequencing, and integrated care networks support rapid clinical translation of novel assays, while market participants must navigate reimbursement complexity and heterogeneous laboratory accreditation landscapes. This region often leads in companion diagnostic collaborations between device makers and pharmaceutical sponsors, producing rich pipelines for implementation studies and real-world evidence generation.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare financing models create a patchwork of adoption scenarios that favor regionally tailored strategies. High-capacity centers in Western Europe act as hubs for advanced diagnostics and multicenter studies, whereas other subregions prioritize cost-effective assays and scalable workflows that can operate in constrained settings. Cross-border collaborations within Europe are increasingly important for harmonizing standards, enabling data sharing, and accelerating multicountry trials that validate biomarker utility across diverse populations.

In Asia-Pacific, rapid expansion of laboratory capacity, increasing public and private investment in genomics, and large patient populations present substantial opportunities for scaling both diagnostic services and biomarker-driven clinical research. Nevertheless, varying levels of regulatory maturity and differences in reimbursement create a landscape where local partnerships, technology transfer, and capacity building are critical to achieving broad access. Across all regions, supply chain considerations, workforce training, and data governance frameworks will determine the pace and equity of clinical implementation, making regionally informed strategies essential for sustained impact.

How strategic specialization, integrated service models, and collaborative companion diagnostic partnerships define competitive advantage and enable scalable clinical adoption

Leading companies and research organizations are differentiating through specialization, vertically integrated offerings, and collaborative models that combine assay development with informatics and clinical support. Some firms concentrate on platform excellence-delivering validated instruments, consumables, and standardized workflows that enable high-throughput diagnostics-while others focus on niche clinical applications such as minimal residual disease detection or complex structural variant resolution. Strategic partnerships between technology providers and pharmaceutical developers are increasingly common, aligning companion diagnostic development with therapeutic pipelines to streamline regulatory approval and market access.

Competitive dynamics hinge on the ability to demonstrate analytical validity, clinical utility, and operational scalability. Organizations that invest in rigorous multicenter validation studies and interoperable reporting standards gain credibility with laboratories and payers. In addition, companies that provide end-to-end solutions-including sample logistics, bioinformatics, and clinician-facing interpretation-are better positioned to capture value in hospital and laboratory settings that prefer turnkey implementations.

Mergers, acquisitions, and licensing agreements continue to shape the landscape as firms seek to broaden their portfolios and secure access to complementary technologies and regional distribution networks. Simultaneously, a growing cohort of specialized service providers supports research institutes and pharmaceutical companies with bespoke assay development, biomarker validation, and translational analytics. This ecosystem of platform vendors, service providers, and clinical adopters is creating multiple pathways for innovation diffusion, each with distinct implications for pricing, reimbursement negotiation, and long-term sustainability.

Actionable strategic priorities for leaders to build supply resilience, clinical validation pathways, and interoperable services that accelerate uptake and stewardship of profiling solutions

Industry leaders should prioritize investments that reinforce resilience, clinical relevance, and seamless integration into care pathways. Strengthening supply chain transparency and sourcing flexibility will mitigate tariff and logistics risks, while targeted investments in regional manufacturing or distribution can shorten lead times and stabilize access to critical consumables. Concurrently, organizations should invest in cross-platform validation studies that demonstrate concordance between technologies and support interoperability of clinical reports across electronic health systems.

From a product and clinical strategy standpoint, companies should align assay development with high-impact clinical use cases such as therapy selection and minimal residual disease monitoring, producing evidence packages that address payer and clinician requirements. Collaboration with pharmaceutical sponsors for co-development of companion diagnostics and with academic centers for prospective validation studies will accelerate clinical uptake. Equally important is building interpretive services and decision-support tools that translate complex molecular results into actionable clinical recommendations, reducing adoption friction among clinicians.

Operationally, stakeholders must expand workforce training and establish robust quality systems to sustain reproducibility as testing volumes grow. Leaders should also engage proactively with regulators and payers to shape evidence expectations and reimbursement frameworks, emphasizing real-world performance and patient-centric outcomes. Finally, adopting flexible commercial models-ranging from centralized reference testing to reagent-as-a-service-can help organizations tailor offerings to diverse end-user needs and create multiple revenue streams while maintaining patient access.

A transparent and practitioner-focused methodology combining expert engagements, technical literature synthesis, and cross-validation against laboratory standards to ensure actionable insights

The research methodology underpinning this executive summary combined primary and secondary sources, expert interviews, and structured synthesis to produce a balanced assessment of technological, clinical, and commercial trends. Primary inputs included conversations with laboratory directors, clinical investigators, and industry executives to capture operational realities, evidence requirements, and adoption barriers. These qualitative engagements were supplemented by careful review of peer-reviewed literature, regulatory guidance, and technical white papers to ground technological descriptions and clinical use-case delineations.

Analytic approaches emphasized triangulation: cross-referencing expert perspectives with published validation studies and technical specifications to identify consistent patterns of performance and adoption. Particular attention was paid to assay sensitivity, specificity, and workflow compatibility, as well as to logistics such as sample stability and cold chain dependencies. Where possible, methodological choices were benchmarked against established laboratory standards and consensus recommendations to ensure practical relevance.

Limitations of the methodology include potential bias inherent in selective expert sampling and variability in publicly available technical documentation. To mitigate these constraints, the study prioritized sources with direct operational experience and sought corroboration across multiple stakeholder types. The result is a defensible, practitioner-oriented set of insights designed to support strategic decision-making without relying on proprietary market estimates.

Final synthesis underscoring the critical interplay of technology, evidence, and operational resilience that will determine which profiling approaches achieve sustained clinical impact

In conclusion, cancer profiling is at an inflection point where technical advances, regulatory evolution, and shifting supply chain considerations converge to create both opportunities and operational challenges. The most successful organizations will be those that integrate robust assay technology with validated workflows, responsive supply strategies, and clinician-centered reporting that directly support therapeutic decision-making. Emphasizing cross-platform validation and evidence generation will be critical for translating analytical capabilities into routine clinical use.

Moreover, regional heterogeneity and policy dynamics will require adaptive commercial models and sustained stakeholder engagement. By focusing on resilience, clinical alignment, and partnerships that bridge technological and therapeutic development, leaders can accelerate the adoption of high-impact profiling solutions while safeguarding continuity of care. The insights presented here aim to equip senior decision-makers with the context and priorities needed to navigate this evolving landscape and to identify the investments that will yield enduring clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Profiling Market, by Cancer Type

  • 8.1. Hematologic Malignancies
    • 8.1.1. Leukemia
    • 8.1.2. Lymphoma
    • 8.1.3. Multiple Myeloma
  • 8.2. Solid Tumors
    • 8.2.1. Breast
    • 8.2.2. Colorectal
    • 8.2.3. Lung
    • 8.2.4. Prostate

9. Cancer Profiling Market, by Technology

  • 9.1. Fluorescence In Situ Hybridization
  • 9.2. Immunohistochemistry
  • 9.3. Microarray
  • 9.4. Next Generation Sequencing
    • 9.4.1. Long Read Sequencing
    • 9.4.2. Short Read Sequencing
  • 9.5. Polymerase Chain Reaction

10. Cancer Profiling Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
    • 10.1.3. Whole Blood
  • 10.2. Saliva
  • 10.3. Urine

11. Cancer Profiling Market, by Biomarker Type

  • 11.1. DNA-Based
  • 11.2. Protein-Based
  • 11.3. RNA-Based

12. Cancer Profiling Market, by Application

  • 12.1. Diagnosis
  • 12.2. Monitoring
    • 12.2.1. Liquid Biopsy
    • 12.2.2. Minimal Residual Disease
  • 12.3. Prognosis
  • 12.4. Research
  • 12.5. Therapy Selection
    • 12.5.1. Companion Diagnostics
    • 12.5.2. Pharmacogenomics

13. Cancer Profiling Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals
  • 13.3. Pharmaceutical Companies
  • 13.4. Research Institutes

14. Cancer Profiling Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Profiling Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Profiling Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Profiling Market

18. China Cancer Profiling Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. 4basecare Onco Solutions Private Limited
  • 19.6. ACT Genomics Co., Ltd. by Prenetics Global Limited
  • 19.7. Agendia, Inc.
  • 19.8. Agilent Technologies, Inc.
  • 19.9. BostonGene Corporation
  • 19.10. Caris Life Sciences
  • 19.11. Exact Sciences Corporation
  • 19.12. F. Hoffmann-La Roche AG
  • 19.13. GENINUS Inc.
  • 19.14. Genomic Life
  • 19.15. GenScript Biotech Corporation
  • 19.16. Guardant Health, Inc.
  • 19.17. Hologic, Inc.
  • 19.18. HTG Molecular Diagnostics, Inc.
  • 19.19. Illumina, Inc.
  • 19.20. IMBdx, Inc.
  • 19.21. Laboratory Corporation of America Holdings
  • 19.22. Lucence Health, Inc.
  • 19.23. Merck KGaA
  • 19.24. NanoString Technologies, Inc.
  • 19.25. Neogenomics, Inc.
  • 19.26. Nonacus Limited
  • 19.27. OncoDNA S.A.
  • 19.28. Oncompass Medicine Hungary Kft.
  • 19.29. Paragon Genomics, Inc.
  • 19.30. Personalis, Inc.
  • 19.31. Perthera, Inc.
  • 19.32. Qiagen N.V.
  • 19.33. Renovaro Biosciences Inc.
  • 19.34. Strand Life Sciences
  • 19.35. Sysmex Corporation
  • 19.36. Takara Bio Inc.
  • 19.37. Tempus Labs Inc.
  • 19.38. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER PROFILING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER PROFILING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER PROFILING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER PROFILING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER PROFILING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER PROFILING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER PROFILING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS CANCER PROFILING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL CANCER PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. GCC CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 250. GCC CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 253. GCC CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. GCC CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 255. GCC CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. GCC CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. GCC CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 258. GCC CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 259. GCC CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. G7 CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. G7 CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 292. G7 CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. G7 CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 294. G7 CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. G7 CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 297. G7 CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 298. G7 CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. NATO CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. NATO CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 305. NATO CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 307. NATO CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. NATO CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. NATO CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 310. NATO CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 311. NATO CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)